RAMIE Versus MIE for Resectable Esophageal Cancer, a Randomized Controlled Trial (ROBOT-2 Trial).

BACKGROUND: For patients with esophageal cancer, radical esophagectomy with 2-field lymphadenectomy is the cornerstone of the multimodality treatment with curative intent. Both, conventional minimally invasive esophagectomy (MIE) and robot assisted minimally invasive esophagectomy (RAMIE) were shown to be superior compared to open transthoracic esophagectomy considering postoperative complications. However, no randomized comparison was made until now to compare MIE to RAMIE OBJECTIVES: The objective is to evaluate the extent of lymph node dissection, efficacy, risks, quality of life and cost-

Trial Details

NCT ID
NCT04306458
Phase
NA
Sponsor
University Medical Center Mainz
Status
RECRUITING
Cancer Type
Adenocarcinoma Esophageal Cancer
Interventions
  • Minimally invasive esophagectomy
  • daVinci Xi system
Locations (sample)
  • Mainz, Germany|49.98185,8.28008

Key Eligibility Criteria

  • Histologically proven adenocarcinoma of the intrathoracic esophagus and gastroesophageal junction (including Siewert I and II)
  • Surgically resectable (T1-4a, N0-3, M0)
  • Age ≥ 18 and ≤ 90 years
  • European Clinical Oncology Group (ECOG) performance status 0,1 or 2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Esophageal Cancer Trials on Trialify →